Roflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

1. Treating chronic obstructive pulmonary disease with ensifentrine: a systematic review.Frontiers in medicine · 2025
   Pooled it
2. Pharmacokinetics of Roflumilast Cream in Chronic Plaque Psoriasis: Data from Phase I to Phase III Studies.American journal of clinical dermatology · 2023
   Trial
3. Bronchial Rheoplasty for Treatment of Chronic Bronchitis. Twelve-Month Results from a Multicenter Clinical Trial.American journal of respiratory and critical care medicine · 2020
   Trial
4. Exploring the Therapeutic Landscape: A Narrative Review on Topical and Oral Phosphodiesterase-4 Inhibitors in Dermatology.Pharmaceutics · 2025
   Review
5. Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer.Cell death discovery · 2024
   Article
6. Long-Term Safety of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease, a Multinational Observational Database Cohort Study.International journal of chronic obstructive pulmonary disease · 2024
   Observational
7. Topical Application of Dipyridamole and Roflumilast Combination Nanoparticles Loaded Nanoemulgel for the Treatment of Psoriasis in Rats.International journal of nanomedicine · 2024
   Article
8. Investigation of apoptotic and autophagic effects of chronic roflumilast use on testicular tissue in rats by immunohistochemical and immunofluorescence methods.Iranian journal of basic medical sciences · 2023
   Article
9. A four-part guide to lung immunology: Invasion, inflammation, immunity, and intervention.Frontiers in immunology · 2023
   Review
10. The Role of the Pharmacist in Optimizing Outcomes With Roflumilast, a PDE4 Inhibitor for the Treatment of COPD.Journal of pharmacy practice · 2022
    Review
11. An inhibitor of RORγ for chronic pulmonary obstructive disease treatment.Scientific reports · 2022
    Article
12. G-Protein Coupled Receptor Signaling and Mammalian Target of Rapamycin Complex 1 Regulation.Molecular pharmacology · 2022
    Review
13. Roflumilast Powders for Chronic Obstructive Pulmonary Disease: Formulation Design and the Influence of Device, Inhalation Flow Rate, and Storage Relative Humidity on Aerosolization.Pharmaceutics · 2021
    Article
14. Scope of adjuvant therapy using roflumilast, a PDE-4 inhibitor against COVID-19.Pulmonary pharmacology & therapeutics · 2021
    Review
15. Type-4 Phosphodiesterase (PDE4) Blockade Reduces NETosis in Cystic Fibrosis.Frontiers in pharmacology · 2021
    Article
16. New putative insights into neprilysin (NEP)-dependent pharmacotherapeutic role of roflumilast in treating COVID-19.European journal of pharmacology · 2020
    Review
17. Phosphodiesterase 4B: Master Regulator of Brain Signaling.Cells · 2020
    Review
18. Therapies that enhance pulmonary vascular NO-signaling in the neonate.Nitric oxide : biology and chemistry · 2020
    Review
19. Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair.International journal of molecular sciences · 2017
    Review
20. Co-inhalation of roflumilast, rather than formoterol, with fluticasone more effectively improves asthma in asthmatic mice.Experimental biology and medicine (Maywood, N.J.) · 2017
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.